On December 14, 2022, we had the opportunity to briefly present our vision and strategy as a new member of the Research Association for Medicinal Products
Corporate strategy
EVANIUM develops innovative, IP-protected health ingredients based on secondary plant compounds for the food industry and the pharmaceutical sector. The company focuses in particular on bioactive flavonoids for consumer care and OTC applications.
Phytochemicals, and polyphenols in particular, are characterized by a multitude of positive health effects. At the same time, consumer interest in plant-based health products is growing steadily. However, many flavonoids have problematic physicochemical properties, and their biological activity is often insufficiently researched. Therefore, using these substances remains a significant challenge for the industry.
Through its vertically integrated technology, EVANIUM also gives partner companies access to a pool of plant-based ingredients and extracts. These have significantly improved technical properties, particularly in terms of water solubility, stability and bioavailability.
Core technologies and services
OPTISOLV® platform technology significantly improves the properties of problematic plant extracts. This also applies to poorly soluble and barely permeable secondary plant substances. The ingredients are formulated as a novel solid dispersion in a starch carrier. As a result, they offer excellent solubility, stability and compressibility while maintaining a high drug load.
Additionally, we research polyphenolic active ingredients for novel applications. We test their biological activity using in silico and in vitro screening methods.
EVANIUM offers targeted contract development and joint development collaborations to improve existing ingredients. The company also develops its own branded plant-based raw materials using OPTISOLV® Technology.
You can find the article here.
